Non-Stimulant Strattera More Widely Available for Attention-Deficit/Hyperactivity Disorder Patients in Europe (opti news)

home   >   yahoo news

Eli Lilly and Company's Strattera(R), the only approved non-stimulant medication proven clinically effective(1) at treating the potentially serious symptoms of attention-deficit/hyperactivity disorder (ADHD), is now more widely available in Europe, following marketing authorizations granted by regulatory authorities in Germany, The Netherlands and Norway.

- link to Non-Stimulant Strattera More Widely Available for Attention-Deficit/Hyperactivity Disorder Patients in Europe (opti news) -
Last update: 06/01/2005

Recommended Reading

    Immunizing All Children Against Flu Virus May Make Sense. (Status of Antiviral TX Less Clearcut). : An article from: Pediatric News
    The Influenza Pandemic of 1918 (Great Disasters and Their Reforms)
    The Grandmother Doll
    Gel makers hit on SOPs, process validation errors.(Sombra Cosmetics)(Brief Article) : An article from: Validation Times
    Winning the Cold War: Preventing and Curing the Common Cold and Flu (Natural Remedies for Common Ailments and Conditions Ser.)
    Borrowed Light
    Forgiven and Set Free: A Post-Abortion Bible Study for Women
    Armageddon Strain (The Countdown)